Afc-Hd AMS Life Science Reports Strong Mid-Term Results Amid Stable Business Performance

AFC-HD AMS Life Science Co.,Ltd. [2927.T]

TOKYO, Apr 14 (Pulse News Wire) – Afc-hd AMS Life Science CO.,LTD. (2927.T) reported robust mid-term results for the six months ending February 28, 2026.

Revenue reached ¥16.85 billion, up 101.4% compared to the same period last year. Operating profit stood at ¥1.251 billion, marking a 96.6% increase year-over-year. Ordinary profit was recorded at ¥1.194 billion, reflecting a 89.6% growth rate. Net income attributable to parent shareholders amounted to ¥801 million, representing a 90.9% rise from the previous year's interim period. In its pharmaceutical division, the company saw strong sales driven by generic drugs such as 'Pimro Granules' and medical generics like 'Sildenafil Tablets,' 'Finasteride Tablets,' and 'Tadalafil Tablets.' Additionally, increased prices for traditional Chinese medicine formulations since April 2024 contributed positively to profitability. Sales revenue for the pharmaceutical sector grew to ¥1.283 billion, a 103.1% increase from the prior year, while operating profit rose to ¥158 million, a 173.4% improvement.

For the department store business, Sakaya achieved three consecutive profitable quarters through strategic initiatives focusing on tenant operations and capital restructuring. The company plans to distribute a dividend of ¥5 per share for the fiscal year-end. Furthermore, Sakaya secured additional space in Yokosuka City, reducing annual fixed costs by more than 40 million yen and increasing rental income due to the upcoming opening of Round One Japan in summer. In the food service sector, Nasubi experienced significant growth in customer traffic and sales at Shizuoka Prefectural Museum, thanks to successful catering services and media exposure. Asafujis Kitchen’s unagi restaurant also showed improved performance, with plans to reopen a renovated branch in Hamamatsu station area by late May. Looking ahead, AFC-HD AMS Life Science forecasts continued positive trends across all segments, expecting further expansion in sales and profits for the remaining half of the fiscal year.

Original Disclosure (PDF)

🔴 Confidence: Review recommended AI-translated content.